Atopic dermatitis differential diagnosis: Difference between revisions
Line 12: | Line 12: | ||
==Differentiating [Disease name] from other Diseases== | ==Differentiating [Disease name] from other Diseases== | ||
** Seborrhoeic dermatitis | ** Seborrhoeic dermatitis | ||
*** onset during the 1st days or weeks of life, absence of pruritus, and presence of greasy scaling on a yellow-red base | *** onset during the 1st days or weeks of life, absence of pruritus, and presence of greasy scaling on a yellow-red base | ||
*** Involvement of the top of the scalp (cradle cap), axilla, and diaper area makes it more likely the patient has '''seborrheic dermatitis''', vs excoriated dermatitis involving the extensor surfaces, face, and trunk favour '''AE.''' | *** Involvement of the top of the scalp (cradle cap), axilla, and diaper area makes it more likely the patient has '''seborrheic dermatitis''', vs excoriated dermatitis involving the extensor surfaces, face, and trunk favour '''AE.''' | ||
** Sarcoptes scabiei | ** Sarcoptes scabiei | ||
*** highly pruritic, erythematous papular lesions. In most cases, the typical burrows can be found on the flexor wrists, finger webs and genitalia. Similar symptoms in other family members | *** highly pruritic, erythematous papular lesions. In most cases, the typical burrows can be found on the flexor wrists, finger webs and genitalia. Similar symptoms in other family members | ||
{| | {| | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! | ! rowspan="5" |Category | ||
! rowspan=" | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
|Etiology | | rowspan="5" |Etiology | ||
| | | rowspan="5" |Inherited | ||
|Acquired | | rowspan="5" |Acquired | ||
|Demography | | rowspan="5" |Demography | ||
|History | | rowspan="5" |History | ||
| colspan=" | | colspan="11" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan=" | ! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan=" | | colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan=" | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
| colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | |||
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | |||
| colspan=" | |||
! colspan=" | |||
|- | |- | ||
! colspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | |||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | |||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | |||
! colspan=" | |||
! rowspan=" | |||
! rowspan=" | |||
|- | |- | ||
! | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Itching | |||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | |||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | |||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP | |||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | |||
!Nail pitting | |||
! colspan="1" rowspan=" | ! rowspan="2" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | |||
! colspan="1" rowspan=" | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | |||
!Other | |||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BUN/Cr | ! rowspan="2" |Electrolytes | ||
!LFT | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BUN/Cr | ||
! rowspan="2" |LFT | |||
|- | |- | ||
! | !Single/ | ||
Multiple | |||
!Rash | |||
!Involved areas | |||
!Pustule | |||
! | |||
! | |||
! | |||
! | ! | ||
!WBC | !WBC | ||
!Hb | !Hb | ||
!Plt | !Plt | ||
|- | |- | ||
| rowspan="10" |Skin disorders | | rowspan="10" |Skin disorders | ||
Line 139: | Line 70: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 144: | Line 78: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 149: | Line 84: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 163: | Line 99: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 168: | Line 107: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 173: | Line 113: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 187: | Line 128: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 192: | Line 136: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 197: | Line 142: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 211: | Line 157: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 216: | Line 165: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 221: | Line 171: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 229: | Line 180: | ||
|- | |- | ||
|Lichen simplex chronicus | |Lichen simplex chronicus | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 253: | Line 209: | ||
|- | |- | ||
|'''Ichthyosis vulgaris''' | |'''Ichthyosis vulgaris''' | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 277: | Line 238: | ||
|- | |- | ||
|'''Nummular Dermatitis''' | |'''Nummular Dermatitis''' | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 301: | Line 267: | ||
|- | |- | ||
|Netherton syndrome | |Netherton syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 325: | Line 296: | ||
|- | |- | ||
|Dubowitz syndrome | |Dubowitz syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 349: | Line 325: | ||
|- | |- | ||
|Erythrokeratodermia variabilis | |Erythrokeratodermia variabilis | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 372: | Line 353: | ||
| | | | ||
|- | |- | ||
| rowspan=" | | rowspan="7" |Infection | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Dermatophytes | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Dermatophytes | ||
| | | | ||
Line 380: | Line 361: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 385: | Line 369: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 390: | Line 375: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 398: | Line 384: | ||
|- | |- | ||
|Candida | |Candida | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 422: | Line 413: | ||
|- | |- | ||
|Herpes simplex | |Herpes simplex | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 446: | Line 442: | ||
|- | |- | ||
|Staphylococcus aureus | |Staphylococcus aureus | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Molluscum Contagiosum | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 470: | Line 500: | ||
|- | |- | ||
|'''Scabies''' | |'''Scabies''' | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 494: | Line 529: | ||
|- | |- | ||
|HIV | |HIV | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 519: | Line 559: | ||
| rowspan="4" |Immunologic disorders | | rowspan="4" |Immunologic disorders | ||
|Dermatitis herpetiformis | |Dermatitis herpetiformis | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 543: | Line 588: | ||
|- | |- | ||
|Pemphigus foliaceus | |Pemphigus foliaceus | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 567: | Line 617: | ||
|- | |- | ||
|Graft-versus-host disease | |Graft-versus-host disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 591: | Line 646: | ||
|- | |- | ||
|Dermatomyositis | |Dermatomyositis | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 622: | Line 682: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 627: | Line 690: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 632: | Line 696: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 646: | Line 711: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 651: | Line 719: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 656: | Line 725: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 664: | Line 734: | ||
|- | |- | ||
|DiGeorge syndrome | |DiGeorge syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 688: | Line 763: | ||
|- | |- | ||
|Severe combined immunodeficiency (SCID) | |Severe combined immunodeficiency (SCID) | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 712: | Line 792: | ||
|- | |- | ||
|Ataxia telangiectasia | |Ataxia telangiectasia | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 737: | Line 822: | ||
| rowspan="4" |'''Metabolic Diseases''' | | rowspan="4" |'''Metabolic Diseases''' | ||
|Phenylketonuria | |Phenylketonuria | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 761: | Line 851: | ||
|- | |- | ||
|Tyrosinemia | |Tyrosinemia | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 785: | Line 880: | ||
|- | |- | ||
|Histidinemia | |Histidinemia | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 809: | Line 909: | ||
|- | |- | ||
|Multiple carboxylase deficiency | |Multiple carboxylase deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 840: | Line 945: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 845: | Line 953: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 850: | Line 959: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 857: | Line 967: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| | |Niacin (B3) deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 881: | Line 996: | ||
| | | | ||
|- | |- | ||
| | |Pyridoxine (B6) deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
|Biotin (B7) deficiency | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 913: | Line 1,063: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 918: | Line 1,071: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 923: | Line 1,077: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
Line 931: | Line 1,086: | ||
|- | |- | ||
|Histiocytosis X | |Histiocytosis X | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 956: | Line 1,116: | ||
|Medications | |Medications | ||
|Infliximab | |Infliximab | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | |
Revision as of 16:12, 11 October 2018
Atopic dermatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis |
Risk calculators and risk factors forAtopic dermatitis differential diagnosis |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Xyz Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis |
Risk calculators and risk factors for Atopic dermatitis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
Differentiating [Disease name] from other Diseases
- Seborrhoeic dermatitis
- onset during the 1st days or weeks of life, absence of pruritus, and presence of greasy scaling on a yellow-red base
- Involvement of the top of the scalp (cradle cap), axilla, and diaper area makes it more likely the patient has seborrheic dermatitis, vs excoriated dermatitis involving the extensor surfaces, face, and trunk favour AE.
- Sarcoptes scabiei
- highly pruritic, erythematous papular lesions. In most cases, the typical burrows can be found on the flexor wrists, finger webs and genitalia. Similar symptoms in other family members
- Seborrhoeic dermatitis
Category | Diseases | Etiology | Inherited | Acquired | Demography | History | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||||||||||||||
Appearance | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | CBC | ESR/CRP | Electrolytes | BUN/Cr | LFT | ||||||||||||||||
Single/
Multiple |
Rash | Involved areas | Pustule | WBC | Hb | Plt | ||||||||||||||||||||||
Skin disorders | Allergic contact dermatitis | |||||||||||||||||||||||||||
Irritant contact dermatitis | ||||||||||||||||||||||||||||
Seborrheic dermatitis | ||||||||||||||||||||||||||||
Psoriasis | ||||||||||||||||||||||||||||
Lichen simplex chronicus | ||||||||||||||||||||||||||||
Ichthyosis vulgaris | ||||||||||||||||||||||||||||
Nummular Dermatitis | ||||||||||||||||||||||||||||
Netherton syndrome | ||||||||||||||||||||||||||||
Dubowitz syndrome | ||||||||||||||||||||||||||||
Erythrokeratodermia variabilis | ||||||||||||||||||||||||||||
Infection | Dermatophytes | |||||||||||||||||||||||||||
Candida | ||||||||||||||||||||||||||||
Herpes simplex | ||||||||||||||||||||||||||||
Staphylococcus aureus | ||||||||||||||||||||||||||||
Molluscum Contagiosum | ||||||||||||||||||||||||||||
Scabies | ||||||||||||||||||||||||||||
HIV | ||||||||||||||||||||||||||||
Immunologic disorders | Dermatitis herpetiformis | |||||||||||||||||||||||||||
Pemphigus foliaceus | ||||||||||||||||||||||||||||
Graft-versus-host disease | ||||||||||||||||||||||||||||
Dermatomyositis | ||||||||||||||||||||||||||||
Immune deficiency | Wiskott-Aldrich syndrome | |||||||||||||||||||||||||||
Hyper-IgE syndrome | ||||||||||||||||||||||||||||
DiGeorge syndrome | ||||||||||||||||||||||||||||
Severe combined immunodeficiency (SCID) | ||||||||||||||||||||||||||||
Ataxia telangiectasia | ||||||||||||||||||||||||||||
Metabolic Diseases | Phenylketonuria | |||||||||||||||||||||||||||
Tyrosinemia | ||||||||||||||||||||||||||||
Histidinemia | ||||||||||||||||||||||||||||
Multiple carboxylase deficiency | ||||||||||||||||||||||||||||
Nutritional deficiencies | Zinc deficiency | |||||||||||||||||||||||||||
Niacin (B3) deficiency | ||||||||||||||||||||||||||||
Pyridoxine (B6) deficiency | ||||||||||||||||||||||||||||
Biotin (B7) deficiency | ||||||||||||||||||||||||||||
Malignancy | Mycosis fungoides | |||||||||||||||||||||||||||
Histiocytosis X | ||||||||||||||||||||||||||||
Medications | Infliximab |